Influence of extreme prematurity and bronchopulmonary dysplasia on cardiac function

2021 ◽  
Author(s):  
Jose Carlos Aldana‐Aguirre ◽  
Luke Eckersley ◽  
Abbas Hyderi ◽  
Akiko Hirose ◽  
Jutta van den Boom ◽  
...  

2019 ◽  
Vol 97 (3) ◽  
pp. 197-205 ◽  
Author(s):  
Mark A. Underwood ◽  
Stephen Wedgwood ◽  
Satyan Lakshminrusimha ◽  
Robin H. Steinhorn

In the premature infant, poor growth in utero (fetal growth restriction) and in the first weeks of life (postnatal growth restriction) are associated with increased risk for bronchopulmonary dysplasia and pulmonary hypertension. In this review, we summarize the epidemiologic data supporting these associations, present a novel rodent model of postnatal growth restriction, and review 5 promising mechanisms by which poor nutrition may affect the developing lung. These observations support the hypothesis that nutritional and (or) pharmacologic interventions early in life may be able to decrease risk of the pulmonary complications of extreme prematurity.



2004 ◽  
Vol 24 (12) ◽  
pp. 769-774 ◽  
Author(s):  
Kamlesh Athavale ◽  
Nelson Claure ◽  
Carmen D'Ugard ◽  
Ruth Everett ◽  
Sethuraman Swaminathan ◽  
...  


2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Megan O'Reilly ◽  
Bernard Thébaud

Bronchopulmonary dysplasia (BPD) is the chronic lung disease of prematurity that affects very preterm infants. Although advances in perinatal care have changed the course of lung injury and enabled the survival of infants born as early as 23-24 weeks of gestation, BPD still remains a common complication of extreme prematurity, and there is no specific treatment for it. Furthermore, children, adolescents, and adults who were born very preterm and developed BPD have an increased risk of persistent lung dysfunction, including early-onset emphysema. Therefore, it is possible that early-life pulmonary insults, such as extreme prematurity and BPD, may increase the risk of COPD later in life, especially if exposed to secondary challenges such as respiratory infections and/or smoking. Recent advances in our understanding of stem/progenitor cells and their potential to repair damaged organs offer the possibility of cell-based treatments for neonatal and adult lung injuries. This paper summarizes the long-term pulmonary outcomes of preterm birth and BPD and discusses the recent advances of cell-based therapies for lung diseases, with a particular focus on BPD and COPD.



2019 ◽  
Vol 7 (2) ◽  
pp. 26 ◽  
Author(s):  
Bibhuti Das ◽  
Michelle-Marie Jadotte ◽  
Jaime Mills ◽  
Kak-Chen Chan

Bronchopulmonary dysplasia (BPD) is the most common respiratory sequelae of prematurity and histopathologically features fewer, dysmorphic, pulmonary arteries. We present our experience with the digital subtraction pulmonary angiography (DSPA) findings of a segmental vascular filling abnormality in three children who were born at extreme prematurity and have pulmonary hypertension due to severe BPD. Our preliminary data suggest that DSPA may be useful in evaluating the severity of pulmonary vascular disease in children with BPD.



CHEST Journal ◽  
1991 ◽  
Vol 100 (3) ◽  
pp. 721-725 ◽  
Author(s):  
Jean-Paul Praud ◽  
Françoise Cavailloles ◽  
Katem Boulhadour ◽  
Mayalen DeRecondo ◽  
Christian Guilleminault ◽  
...  


1996 ◽  
Vol 155 (7) ◽  
pp. 622-622 ◽  
Author(s):  
D. Trevisanuto ◽  
O. Milanesi ◽  
F. Cantarutti ◽  
V. Zanardo




2018 ◽  
Vol 107 (5) ◽  
pp. 811-821 ◽  
Author(s):  
Ann Hellström ◽  
Karin Källén ◽  
Birgitta Carlsson ◽  
Gerd Holmström ◽  
Peter Jakobsson ◽  
...  


2014 ◽  
Vol 307 (12) ◽  
pp. L948-L958 ◽  
Author(s):  
Megan O'Reilly ◽  
Bernard Thébaud

Bronchopulmonary dysplasia (BPD) is the chronic lung disease of prematurity that affects very preterm infants. Although advances in perinatal care have enabled the survival of infants born as early as 23–24 wk of gestation, the challenge of promoting lung growth while protecting the ever more immature lung from injury is now bigger. Consequently, BPD remains one of the most common complications of extreme prematurity and still lacks specific treatments. Progress in our understanding of BPD and the potential of developing therapeutic strategies have arisen from large (baboons, sheep, and pigs) and small (rabbits, rats, and mice) animal models. This review focuses specifically on the use of the rat to model BPD and summarizes how the model is used in various research studies and the advantages and limitations of this particular model, and it highlights recent therapeutic advances in BPD by using this rat model.





Sign in / Sign up

Export Citation Format

Share Document